Baidu
map

武汉金银谭医院的临床研究证实,lopinavir-ritonavir抗HIV组合可减轻新冠COVID-19患者症状

2020-04-08 MedSci原创 MedSci原创

在开展lopinavir-ritonavir临床研究时,全球仅有500例新冠病毒COVID-19感染患者。

将lopinavir-ritonavir联合用药与COVID-19的标准护理比较的临床试验结果表明,该HIV疗法在抗新冠病毒中很有希望。该发现将被视为即将到来的COVid-19 therapY(RECOVERY)试验随机评估的一部分。

在开展lopinavir-ritonavir临床研究时,全球仅有500例新冠病毒COVID-19感染患者。

武汉金银谭医院的研究人员纳入了199例COVID-19患者,使用lopinavir-ritonavir的HIV抗病毒药或标准疗法进行干预。结果显示,使用lopinavir-ritonavir治疗的患者的症状改善快于仅接受标准治疗的患者。

兰卡斯特大学数学与统计学系医学和药物统计学研究组的Thomas Jaki教授表示:"结果令人鼓舞,希望在未来几周内将这些治疗方法纳入常规治疗。"

根据Jaki教授的说法,该研究的结果将被视为即将进行的COVid-19 therapY(RECOVERY)试验随机评估的一部分。RECOVERY被设计为一个试验平台,用于评估大约30种被认为有可能用于COVID-19的疗法。

原始出处:

https://www.europeanpharmaceuticalreview.com/news/116491/positive-results-from-initial-lopinavir-ritonavir-covid-19-clinical-trial/

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1793391, encodeId=f90d1e93391de, content=<a href='/topic/show?id=318915509d6' target=_blank style='color:#2F92EE;'>#ritonavir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15509, encryptionId=318915509d6, topicName=ritonavir)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sun Jan 03 18:26:43 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297423, encodeId=5091129e42357, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Apr 10 02:26:43 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027677, encodeId=96e3102e677cd, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Apr 08 14:26:43 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1793391, encodeId=f90d1e93391de, content=<a href='/topic/show?id=318915509d6' target=_blank style='color:#2F92EE;'>#ritonavir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15509, encryptionId=318915509d6, topicName=ritonavir)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sun Jan 03 18:26:43 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297423, encodeId=5091129e42357, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Apr 10 02:26:43 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027677, encodeId=96e3102e677cd, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Apr 08 14:26:43 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1793391, encodeId=f90d1e93391de, content=<a href='/topic/show?id=318915509d6' target=_blank style='color:#2F92EE;'>#ritonavir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15509, encryptionId=318915509d6, topicName=ritonavir)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sun Jan 03 18:26:43 CST 2021, time=2021-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297423, encodeId=5091129e42357, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Fri Apr 10 02:26:43 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1027677, encodeId=96e3102e677cd, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Wed Apr 08 14:26:43 CST 2020, time=2020-04-08, status=1, ipAttribution=)]
    2020-04-08 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关资讯

日本的干细胞疗法HLCM051,正在开发用于新冠病毒COVID-19感染引起的急性呼吸窘迫综合症

根据武汉市首批新型冠状病毒(COVID-19)患者的数据,住院的31%至41.8%的患者患有ARDS,而患有ARDS的患者中有54%至93%死亡,表明ARDS是COVID-19患者死亡的主要原因。

Baidu
map
Baidu
map
Baidu
map